Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Aspirin (Primary) ; Clopidogrel (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms ATAMIS
- 03 Dec 2022 The study protocol amended as study phase changed to Phase 3 from Phase 1.
- 03 Dec 2022 Status changed from recruiting to completed.
- 20 Feb 2022 Planned End Date changed from 30 Apr 2022 to 30 Dec 2022.